EDITOR-Partial or total glucocerebrosidase (GBA) gene deletions and genetic rearrangements between the functional GBA gene and its highly homologous pseudogene ( GBA) have been reported as pitfalls in diagnostic mutation analysis leading to incorrect genotyping in Gaucher disease (GD, MIM 230800, 230900, 231000). In particular, homozygosity for 1226G/1226G has been misdiagnosed in the presence of both deletions and complex alleles. [1] [2] [3] [4] [5] [6] Because of the necessity selectively to amplify functional GBA sequences from unprocessed pseudogene ( GBA) ones, currently available PCR based techniques make use of primers either in or around the 55 bp pseudogene gap. [7] [8] [9] [10] [11] [12] Therefore, if a deletion or a recombination event is present in sites where one of the primers has to bind, the use of these oligonucleotides that hybridise only with the other allele may produce an apparently homozygous genotype, which can lead to incorrect genotyping and unreliable genetic counselling for patients and their families. Thus, as soon as the rapid screening techniques proved occasionally to be misleading in diagnostic mutation analysis, the laboratories that make use of PCR based methods were warned to pay particular attention to this fact.
To ascertain accidental misgenotyping in a panel of GD patients, molecularly characterised by conventional techniques, 13 we have adapted a simple non-isotopic PCR based method from the isotopic one described by Beutler and Gelbart. 1 The procedure is based on simultaneous GBA and GBA amplification and subsequent comparison of light intensity between the PCR fragments of the gene and the internal control pseudogene. The approach has been used to re-examine 34 patients who were previously genotyped as homozygotes (15 for 1448C (L444P), 14 for 1226G (N370S), one for 1342C (D409H), and four for unique mutations) as well as all patients who had one or both alleles still unidentified, 42 and three respectively. This latter group was reanalysed to try to discover whether deletions or rearrangements had been the cause of the failed identification.
Of a total of 79 GD patients, the PCR based approach allowed us to select six samples ( fig   1A) . In the six PCR products, visualised by ethidium bromide staining, the GBA band was markedly less intense than that of the GBA, whereas in normal conditions the GBA and GBA products gave two bands of approximately the same intensity. To address the hypothesis that one allele could be partially deleted in the six samples, a long template PCR was used to diVerentiate gene from pseudogene, as already described by Tayebi et al. (fig 1B) , but simultaneously showed, in the other three patients, an extra shorter fragment besides the expected GBA and GBA products.
To characterise the nature of this latter alteration, the shorter fragment was cloned and sequenced. A new recombinant allele was identified in two patients who had been diagnosed as having the 1226G/1226G genotype and in one with both alleles still unidentified. 5 On the other hand, in the other three patients, to characterise the deletion encompassing the amplified sequences (intron 1-exon 11), a quantitative fluorescent PCR based technique was adapted from the method described by Woodward et al. 14 Two GBA: GBA ratio values were examined for each sample in exons 2-3 (results not shown) and exon 9 (fig 2) . Two pairs of 20 bp primers (one labelled with the fluorescent phosphoramidite (FAM) at the 5' end) were designed on gene/pseudogene homologous sequences flanking pseudogene gaps making it possible to generate two distinct products. The primers encompassing the deleted 55 bp portion at exon 9 were 5' FAM-ACCTACACTCTCT GGGGACC 3' (forward) and 5' TTCAGCCC ACTTCCCAGACC 3' (reverse). The primers around the pseudogene gap in intron 2 were 5' FAM-TGAGTGACTGAGACCAACTT (forward) and 5' GAAGCTTTTAGGGATGCA GG 3' (reverse). An automated DNA sequencer was used to quantify the fluorescently labelled PCR products. Electropherograms showed two peaks representing gene and pseudogene fragments; dosage estimates were obtained by comparison of the area under the peak correlating to the quantity of fluorescent signal incorporated by the labelled primer. As expected, the GBA: GBA ratio was 1:1 in the control, whereas in the three suspected patients it was 0.5:1, corresponding to one and two copies of the gene and pseudogene, respectively. Using such a technique, the complete gene deletion was confirmed in three patients previously genotyped as 1226G/1226G, and in five unaVected relatives who were classified as non-carriers by conventional screening methods. Nevertheless, it must be admitted that quantitative assay can be aVected by several factors, such as non-uniform amplification of the GBA and GBA fragments as well as the quality of genomic DNA.
In conclusion, the simple non-isotopic PCR based method, used by us to ascertain accidental misgenotyping, enabled us to select six (five apparently homozygous for 1226G/ 1226G and one with both alleles still undetected) of the 79 previously genotyped patients, so that they could be correctly genotyped at a later time. It must, however, be admitted that the approach is not diagnostically useful because of inherent limitations in its use. As a matter of fact, the method based on simultaneous GBA and GBA amplification and comparison of light intensity between the PCR fragments allows only an approximate valuation of the amount of template requiring further specific investigation. Nevertheless, it proved to be suitable for pointing out pitfalls, especially when it is not possible to quantify the number of GBA gene copies, and the parents are not available for carrier analysis. Recently, the method prompted us to further investigations in another patient with apparent homozygosity for 1226G, leading to the characterisation of an allele with the partial deletion 55. Furthermore, the set up of the quantitative fluorescent PCR, confirming the complete gene deletion in three samples, was useful for assigning the correct genotype to the patients and to discriminate between carriers and non-carriers as well.
Therefore, we emphasise the need for additional techniques in order to refine genotyping for reliable genetic counselling for the patients and their families.
Nomenclature. Nucleotide sequences are numbered from the upstream initiator ATG as proposed by Beutler and Gelbart. 15 The amino acid is from the mature N-terminus; Genbank/ EMBL accession numbers M11080 ( cDNA) and J03059 (DNA). The samples were obtained from the "Cell Lines and DNA Bank from Patients aVected by Genetic Disease" collection supported by Italian Telethon grants (C.52). 
